<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142862">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01822184</url>
  </required_header>
  <id_info>
    <org_study_id>HGT-HIT-090</org_study_id>
    <nct_id>NCT01822184</nct_id>
  </id_info>
  <brief_title>Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)</brief_title>
  <official_title>A Prospective, Longitudinal, Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hunter syndrome (Mucopolysaccharidosis II, [MPS II]) is a rare, genetically linked lysosomal
      storage disease (LSD) caused by deficiency of the enzyme, iduronate-2-sulfatase (I2S). Most
      MPS II patients will present with some degree of neurodevelopmental involvement, ranging
      from severe cognitive impairment and behavioral problems to mildly impaired cognition. This
      is an observational study; no investigational treatment will be administered. The primary
      objective of this study is to evaluate the neurodevelopmental status of pediatric patients
      with MPS II over time and to gain information to guide future treatment studies in this
      patient population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Neurodevelopmental parameters of cognitive function over time in pediatric patients with MPS II</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurodevelopmental parameters of adaptive function over time in pediatric patients with MPS II</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reported adverse events</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Type and severity measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication usage</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Mucopolysaccharidosis II</condition>
  <condition>MPS II</condition>
  <condition>Hunter Syndrome</condition>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <description>Observational non-treatment study</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Genotyping of the iduronate-2-sulfatase gene will be required ONLY for those patients who
      have not had a previous genotyping sample analysis performed at the selected diagnostic
      laboratory.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male MPS II patients between 2-18  years of age at time of informed consent
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must meet all of the following criteria to be considered eligible for enrollment:

          1. a. The patient has a deficiency in iduronate-2-sulfatase enzyme activity AND b. The
             patient has a documented mutation in the iduronate-2-sulfatase gene. OR c. The
             patient has a normal enzyme activity level of one other sulfatase

          2. The patient is male, and is at least 2 years of age and less than 18 years of age at
             the time of informed consent.

          3. The patient must have sufficient auditory capacity at enrollment, with or without
             hearing aids, in the Investigator's judgment to complete the required protocol
             testing, and be compliant with wearing the aids on scheduled study visits.

          4. The patient, patient's parent(s), or legally authorized guardian(s) has voluntarily
             signed an Institutional Review Board / Independent Ethics Committee-approved informed
             consent and/or assent form(s), as applicable.

        Exclusion Criteria:

        Patients who meet any of the following criteria will be excluded from the study.

          1. The patient has clinically significant non-Hunter syndrome-related CNS involvement or
             medical or psychiatric comorbidity(ies) which, in the investigator's judgment, may
             interfere with the accurate administration and interpretation of protocol
             assessments, affect study data, or confound the integrity of study results.

          2. The patient has a general conceptual ability score (GCA) or a developmental quotient
             on the cognitive scale below 55 at Screening.

          3. The patient is participating in an interventional clinical trial or has participated
             in an interventional clinical trial within 30 days prior to enrollment; participation
             in non interventional observational studies is permitted.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Barbier, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shire Human Genetic Therapies</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann Barbier, MD, PhD</last_name>
    <phone>+1-781-482-9282</phone>
    <email>abarbier@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Childrens Hospital &amp; Research Center Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Madden, PNP</last_name>
      <phone>510-428-3885</phone>
      <phone_ext>5745</phone_ext>
      <email>jmadden@mail.cho.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Katz, MSW, LSW</last_name>
      <phone>312-227-6764</phone>
      <email>rkatz@luriechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina (UNC) Health Care</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Preiss, RN</last_name>
      <phone>919-843-5731</phone>
      <email>Heather_Preiss@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Austral</name>
      <address>
        <city>Pilar</city>
        <state>Buenos Aires</state>
        <zip>B1629ODT</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gonzalo Fabro</last_name>
      <phone>+54 0230-448283</phone>
      <email>gfabro@cas.austral.edu.ar</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional De Pediatria</name>
      <address>
        <city>Mexico City</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dámaris Sánchez</last_name>
      <phone>+52 55 108 40 900</phone>
      <email>zefiro728@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Lopez Marin, MD</last_name>
      <phone>+34 650024876</phone>
      <email>lauralmarin@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Willink Biochemical Genetics Unit, St. Mary's Hospital</name>
      <address>
        <city>Manchester</city>
        <state>M13 9wl</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Hepburn</last_name>
      <phone>44 (0)161 701 8313</phone>
      <email>Michelle.Hepburn@wtcrf.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Argentina</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>March 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Central Nervous System (CNS) involvement</keyword>
  <keyword>Neurodevelopmental Status</keyword>
  <keyword>Cognitive impairment</keyword>
  <keyword>Pediatric Hunter syndrome patients</keyword>
  <keyword>Observational study</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
